Meningitis Vaccines Market Insights, Competitive Landscape, and Market Forecast - 2033
Description
The global meningitis vaccines market is witnessing strong growth as healthcare systems worldwide intensify efforts to prevent severe and potentially fatal meningitis infections. Meningitis remains a major public health challenge, particularly among infants, children, adolescents, and vulnerable adult populations. Vaccination continues to be the most effective preventive approach, significantly reducing disease incidence, mortality rates, and long-term neurological complications. Rising awareness, improved access to immunization, and continuous advancements in vaccine technologies are collectively shaping a positive outlook for the global meningitis vaccines market.
Market Insights
The meningitis vaccines market is valued at USD 4.7 billion in 2026 and is expected to reach USD 9.6 billion by 2033, growing at a CAGR of 10.70% during the forecast period. This robust expansion reflects increased government focus on preventive healthcare, wider inclusion of meningitis vaccines in national immunization schedules, and growing investment in vaccine research and manufacturing capabilities. Technological advancements, particularly in conjugate and recombinant vaccine formulations, are enhancing vaccine effectiveness and durability, thereby supporting higher adoption rates across global healthcare systems.
Market Drivers
One of the primary drivers of the meningitis vaccines market is the persistent global burden of meningococcal and bacterial meningitis infections. Periodic outbreaks continue to highlight the urgent need for widespread vaccination, especially in high-risk regions. Increasing birth rates in developing economies, coupled with improving pediatric healthcare access, are further strengthening market demand. Government-led immunization programs, support from international health organizations, and large-scale vaccination initiatives are playing a crucial role in expanding coverage. Additionally, rising awareness among parents, caregivers, and healthcare professionals regarding early immunization is contributing to higher vaccine uptake.
Business Opportunity
The market presents substantial business opportunities for vaccine manufacturers focusing on advanced formulations and expanded serotype coverage. Development of multivalent and combination vaccines offers significant potential by reducing the number of doses required while improving patient compliance. Emerging economies across Asia Pacific, Latin America, and Africa represent untapped markets due to growing healthcare expenditure and expanding immunization infrastructure. Strategic collaborations between pharmaceutical companies, governments, and public health agencies are enabling faster product approvals and wider distribution. Improvements in cold-chain logistics and vaccine storage technologies are also supporting market scalability.
Regional Analysis
North America holds a strong position in the meningitis vaccines market, supported by high awareness levels, advanced healthcare infrastructure, and established vaccination policies. Europe follows closely, driven by widespread adoption of conjugate vaccines and comprehensive public immunization programs. Asia Pacific is expected to experience the fastest growth, supported by large population bases, rising disease awareness, and expanding national vaccination initiatives in countries such as India and China. Latin America is showing steady growth due to improving healthcare access and supportive government policies. The Middle East and Africa region continues to demonstrate rising demand, particularly in meningitis-prone areas, supported by international vaccination and disease prevention programs.
Key Players
Key companies operating in the global meningitis vaccines market include:
• GlaxoSmithKline plc (GSK)
• Pfizer Inc.
• Sanofi S.A. (Sanofi Pasteur)
• Merck & Co., Inc.
• Serum Institute of India Pvt. Ltd.
• CSL Limited (Seqirus)
• Bharat Biotech International Ltd.
• Walvax Biotechnology Co., Ltd.
• Hualan Biological Engineering Inc.
• Chongqing Zhifei Biological Products Co., Ltd.
• Bio-Manguinhos / Fiocruz
• China National Biotec Group (CNBG)
• Bio-Med Pvt. Limited
• Panacea Biotec Ltd.
• Biological E. Limited
These players are actively focused on expanding manufacturing capacity, advancing vaccine technologies, and strengthening global distribution networks to enhance their market presence.
Market Segmentation
By Technology / Formulation
• Conjugate Vaccines
• Polysaccharide Vaccines
• Protein / Recombinant Subunit Vaccines
By Targeted Serotypes (for Meningococcal)
• Serogroup A vaccines
• Serogroup B vaccines
• Serogroup C vaccines
• Serogroup W-135 / Y vaccines
• Combination Pentavalent / Multivalent (A/B/C/W/Y)
By Age Group
• Infants (0–2 years)
• Children & Adolescents (2–18 years)
• Adults (18+ years)
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Government Immunization Programs / Public Health Agencies
• Online Pharmacies & Others
By Geography
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Please note: Delivery Timelines - 5 working days.
Market Insights
The meningitis vaccines market is valued at USD 4.7 billion in 2026 and is expected to reach USD 9.6 billion by 2033, growing at a CAGR of 10.70% during the forecast period. This robust expansion reflects increased government focus on preventive healthcare, wider inclusion of meningitis vaccines in national immunization schedules, and growing investment in vaccine research and manufacturing capabilities. Technological advancements, particularly in conjugate and recombinant vaccine formulations, are enhancing vaccine effectiveness and durability, thereby supporting higher adoption rates across global healthcare systems.
Market Drivers
One of the primary drivers of the meningitis vaccines market is the persistent global burden of meningococcal and bacterial meningitis infections. Periodic outbreaks continue to highlight the urgent need for widespread vaccination, especially in high-risk regions. Increasing birth rates in developing economies, coupled with improving pediatric healthcare access, are further strengthening market demand. Government-led immunization programs, support from international health organizations, and large-scale vaccination initiatives are playing a crucial role in expanding coverage. Additionally, rising awareness among parents, caregivers, and healthcare professionals regarding early immunization is contributing to higher vaccine uptake.
Business Opportunity
The market presents substantial business opportunities for vaccine manufacturers focusing on advanced formulations and expanded serotype coverage. Development of multivalent and combination vaccines offers significant potential by reducing the number of doses required while improving patient compliance. Emerging economies across Asia Pacific, Latin America, and Africa represent untapped markets due to growing healthcare expenditure and expanding immunization infrastructure. Strategic collaborations between pharmaceutical companies, governments, and public health agencies are enabling faster product approvals and wider distribution. Improvements in cold-chain logistics and vaccine storage technologies are also supporting market scalability.
Regional Analysis
North America holds a strong position in the meningitis vaccines market, supported by high awareness levels, advanced healthcare infrastructure, and established vaccination policies. Europe follows closely, driven by widespread adoption of conjugate vaccines and comprehensive public immunization programs. Asia Pacific is expected to experience the fastest growth, supported by large population bases, rising disease awareness, and expanding national vaccination initiatives in countries such as India and China. Latin America is showing steady growth due to improving healthcare access and supportive government policies. The Middle East and Africa region continues to demonstrate rising demand, particularly in meningitis-prone areas, supported by international vaccination and disease prevention programs.
Key Players
Key companies operating in the global meningitis vaccines market include:
• GlaxoSmithKline plc (GSK)
• Pfizer Inc.
• Sanofi S.A. (Sanofi Pasteur)
• Merck & Co., Inc.
• Serum Institute of India Pvt. Ltd.
• CSL Limited (Seqirus)
• Bharat Biotech International Ltd.
• Walvax Biotechnology Co., Ltd.
• Hualan Biological Engineering Inc.
• Chongqing Zhifei Biological Products Co., Ltd.
• Bio-Manguinhos / Fiocruz
• China National Biotec Group (CNBG)
• Bio-Med Pvt. Limited
• Panacea Biotec Ltd.
• Biological E. Limited
These players are actively focused on expanding manufacturing capacity, advancing vaccine technologies, and strengthening global distribution networks to enhance their market presence.
Market Segmentation
By Technology / Formulation
• Conjugate Vaccines
• Polysaccharide Vaccines
• Protein / Recombinant Subunit Vaccines
By Targeted Serotypes (for Meningococcal)
• Serogroup A vaccines
• Serogroup B vaccines
• Serogroup C vaccines
• Serogroup W-135 / Y vaccines
• Combination Pentavalent / Multivalent (A/B/C/W/Y)
By Age Group
• Infants (0–2 years)
• Children & Adolescents (2–18 years)
• Adults (18+ years)
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Government Immunization Programs / Public Health Agencies
• Online Pharmacies & Others
By Geography
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Please note: Delivery Timelines - 5 working days.
Table of Contents
200 Pages
- 1. Executive Summary
- 1.1. Global Meningitis Vaccines Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2026
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. COVID-19 Impact Analysis
- 2.5. Porter's Fiver Forces Analysis
- 2.6. Impact of Russia-Ukraine Conflict
- 2.7. PESTLE Analysis
- 2.8. Regulatory Analysis
- 2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2025-2033
- 2.9.2. Price Impact Factors
- 3. Global Meningitis Vaccines Market Outlook, 2020 - 2033
- 3.1. Global Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
- 3.1.1. Conjugate Vaccines
- 3.1.2. Polysaccharide Vaccines
- 3.1.3. Protein / Recombinant Subunit Vaccines
- 3.2. Global Meningitis Vaccines Market Outlook, by Targeted Serotypes , Value (US$ Bn), 2020-2033
- 3.2.1. Serogroup A vaccines
- 3.2.2. Serogroup B vaccines
- 3.2.3. Serogroup C vaccines
- 3.2.4. Serogroup W-135 / Y vaccines
- 3.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
- 3.3. Global Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
- 3.3.1. Infants (0–2 years)
- 3.3.2. Children & Adolescents (2–18 years)
- 3.3.3. Adults (18+ years)
- 3.4. Global Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
- 3.4.1. Hospital Pharmacies
- 3.4.2. Retail Pharmacies
- 3.4.3. Government Immunization Programs / Public Health Agencies
- 3.4.4. Online Pharmacies & Others
- 3.5. Global Meningitis Vaccines Market Outlook, by Region, Value (US$ Bn), 2020-2033
- 3.5.1. North America
- 3.5.2. Europe
- 3.5.3. Asia Pacific
- 3.5.4. Latin America
- 3.5.5. Middle East & Africa
- 4. North America Meningitis Vaccines Market Outlook, 2020 - 2033
- 4.1. North America Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
- 4.1.1. Conjugate Vaccines
- 4.1.2. Polysaccharide Vaccines
- 4.1.3. Protein / Recombinant Subunit Vaccines
- 4.2. North America Meningitis Vaccines Market Outlook, by Targeted Serotypes , Value (US$ Bn), 2020-2033
- 4.2.1. Serogroup A vaccines
- 4.2.2. Serogroup B vaccines
- 4.2.3. Serogroup C vaccines
- 4.2.4. Serogroup W-135 / Y vaccines
- 4.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
- 4.3. North America Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
- 4.3.1. Infants (0–2 years)
- 4.3.2. Children & Adolescents (2–18 years)
- 4.3.3. Adults (18+ years)
- 4.4. North America Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
- 4.4.1. Hospital Pharmacies
- 4.4.2. Retail Pharmacies
- 4.4.3. Government Immunization Programs / Public Health Agencies
- 4.4.4. Online Pharmacies & Others
- 4.5. North America Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 4.5.1. U.S. Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 4.5.2. U.S. Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 4.5.3. U.S. Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 4.5.4. U.S. Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 4.5.5. Canada Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 4.5.6. Canada Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 4.5.7. Canada Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 4.5.8. Canada Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 4.6. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Meningitis Vaccines Market Outlook, 2020 - 2033
- 5.1. Europe Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
- 5.1.1. Conjugate Vaccines
- 5.1.2. Polysaccharide Vaccines
- 5.1.3. Protein / Recombinant Subunit Vaccines
- 5.2. Europe Meningitis Vaccines Market Outlook, by Targeted Serotypes , Value (US$ Bn), 2020-2033
- 5.2.1. Serogroup A vaccines
- 5.2.2. Serogroup B vaccines
- 5.2.3. Serogroup C vaccines
- 5.2.4. Serogroup W-135 / Y vaccines
- 5.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
- 5.3. Europe Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
- 5.3.1. Infants (0–2 years)
- 5.3.2. Children & Adolescents (2–18 years)
- 5.3.3. Adults (18+ years)
- 5.4. Europe Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies
- 5.4.3. Government Immunization Programs / Public Health Agencies
- 5.4.4. Online Pharmacies & Others
- 5.5. Europe Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 5.5.1. Germany Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.2. Germany Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.3. Germany Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.4. Germany Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.5.5. Italy Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.6. Italy Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.7. Italy Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.8. Italy Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.5.9. France Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.10. France Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.11. France Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.12. France Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.5.13. U.K. Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.14. U.K. Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.15. U.K. Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.16. U.K. Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.5.17. Spain Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.18. Spain Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.19. Spain Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.20. Spain Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.5.21. Russia Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.22. Russia Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.23. Russia Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.24. Russia Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.5.25. Rest of Europe Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 5.5.26. Rest of Europe Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 5.5.27. Rest of Europe Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 5.5.28. Rest of Europe Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 5.6. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Meningitis Vaccines Market Outlook, 2020 - 2033
- 6.1. Asia Pacific Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
- 6.1.1. Conjugate Vaccines
- 6.1.2. Polysaccharide Vaccines
- 6.1.3. Protein / Recombinant Subunit Vaccines
- 6.2. Asia Pacific Meningitis Vaccines Market Outlook, by Targeted Serotypes , Value (US$ Bn), 2020-2033
- 6.2.1. Serogroup A vaccines
- 6.2.2. Serogroup B vaccines
- 6.2.3. Serogroup C vaccines
- 6.2.4. Serogroup W-135 / Y vaccines
- 6.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
- 6.3. Asia Pacific Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
- 6.3.1. Infants (0–2 years)
- 6.3.2. Children & Adolescents (2–18 years)
- 6.3.3. Adults (18+ years)
- 6.4. Asia Pacific Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies
- 6.4.3. Government Immunization Programs / Public Health Agencies
- 6.4.4. Online Pharmacies & Others
- 6.5. Asia Pacific Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 6.5.1. China Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 6.5.2. China Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 6.5.3. China Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 6.5.4. China Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 6.5.5. Japan Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 6.5.6. Japan Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 6.5.7. Japan Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 6.5.8. Japan Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 6.5.9. South Korea Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 6.5.10. South Korea Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 6.5.11. South Korea Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 6.5.12. South Korea Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 6.5.13. India Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 6.5.14. India Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 6.5.15. India Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 6.5.16. India Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 6.5.17. Southeast Asia Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 6.5.18. Southeast Asia Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 6.5.19. Southeast Asia Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 6.5.20. Southeast Asia Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 6.5.21. Rest of SAO Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 6.5.22. Rest of SAO Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 6.5.23. Rest of SAO Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 6.5.24. Rest of SAO Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 6.6. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Meningitis Vaccines Market Outlook, 2020 - 2033
- 7.1. Latin America Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
- 7.1.1. Conjugate Vaccines
- 7.1.2. Polysaccharide Vaccines
- 7.1.3. Protein / Recombinant Subunit Vaccines
- 7.2. Latin America Meningitis Vaccines Market Outlook, by Targeted Serotypes , Value (US$ Bn), 2020-2033
- 7.2.1. Serogroup A vaccines
- 7.2.2. Serogroup B vaccines
- 7.2.3. Serogroup C vaccines
- 7.2.4. Serogroup W-135 / Y vaccines
- 7.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
- 7.3. Latin America Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
- 7.3.1. Infants (0–2 years)
- 7.3.2. Children & Adolescents (2–18 years)
- 7.3.3. Adults (18+ years)
- 7.4. Latin America Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Government Immunization Programs / Public Health Agencies
- 7.4.4. Online Pharmacies & Others
- 7.5. Latin America Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 7.5.1. Brazil Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 7.5.2. Brazil Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 7.5.3. Brazil Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 7.5.4. Brazil Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 7.5.5. Mexico Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 7.5.6. Mexico Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 7.5.7. Mexico Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 7.5.8. Mexico Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 7.5.9. Argentina Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 7.5.10. Argentina Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 7.5.11. Argentina Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 7.5.12. Argentina Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 7.5.13. Rest of LATAM Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 7.5.14. Rest of LATAM Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 7.5.15. Rest of LATAM Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 7.5.16. Rest of LATAM Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 7.6. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Meningitis Vaccines Market Outlook, 2020 - 2033
- 8.1. Middle East & Africa Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
- 8.1.1. Conjugate Vaccines
- 8.1.2. Polysaccharide Vaccines
- 8.1.3. Protein / Recombinant Subunit Vaccines
- 8.2. Middle East & Africa Meningitis Vaccines Market Outlook, by Targeted Serotypes , Value (US$ Bn), 2020-2033
- 8.2.1. Serogroup A vaccines
- 8.2.2. Serogroup B vaccines
- 8.2.3. Serogroup C vaccines
- 8.2.4. Serogroup W-135 / Y vaccines
- 8.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
- 8.3. Middle East & Africa Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
- 8.3.1. Infants (0–2 years)
- 8.3.2. Children & Adolescents (2–18 years)
- 8.3.3. Adults (18+ years)
- 8.4. Middle East & Africa Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies
- 8.4.3. Government Immunization Programs / Public Health Agencies
- 8.4.4. Online Pharmacies & Others
- 8.5. Middle East & Africa Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 8.5.1. GCC Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 8.5.2. GCC Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 8.5.3. GCC Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 8.5.4. GCC Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 8.5.5. South Africa Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 8.5.6. South Africa Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 8.5.7. South Africa Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 8.5.8. South Africa Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 8.5.9. Egypt Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 8.5.10. Egypt Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 8.5.11. Egypt Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 8.5.12. Egypt Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 8.5.13. Nigeria Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 8.5.14. Nigeria Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 8.5.15. Nigeria Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 8.5.16. Nigeria Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 8.5.17. Rest of Middle East Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
- 8.5.18. Rest of Middle East Meningitis Vaccines Market Outlook, by Targeted Serotypes , 2020-2033
- 8.5.19. Rest of Middle East Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
- 8.5.20. Rest of Middle East Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
- 8.6. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Company Vs Segment Heatmap
- 9.2. Company Market Share Analysis, 2025
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. GlaxoSmithKline plc (GSK)
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Developments
- 9.4.2. Pfizer Inc.
- 9.4.3. Sanofi S.A. (Sanofi Pasteur)
- 9.4.4. Merck & Co., Inc.
- 9.4.5. Serum Institute of India Pvt. Ltd.
- 9.4.6. CSL Limited (Seqirus)
- 9.4.7. Bharat Biotech International Ltd.
- 9.4.8. Walvax Biotechnology Co., Ltd.
- 9.4.9. Hualan Biological Engineering Inc.
- 9.4.10. Chongqing Zhifei Biological Products Co., Ltd.
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
